In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tolmar buys QLT USA

Executive Summary

Drug manufacturer Tolmar Holding has agreed to pay up to $230mm to buy QLT USA, the subsidiary of QLT whose main asset is the injectable prostate cancer therapy Eligard (leuprolide).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Acquisition of Private Biotech
    • Full Acquisition
    • Payment Includes Cash
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register